ArticleBMC gastroenterology2025
Association of cardiometabolic risk burden with gastrointestinal bleeding in aspirin users.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
introductionAspirin is widely used in patients with ischemic cardiovascular diseases, most of whom have cardiometabolic disorders. This study aimed to investigate the impact of cardiometabolic risk burden on first gastrointestinal (GI) bleeding in aspirin users.
methodsThis is a cohort study, including patients with ischemic cardiovascular disease and aspirin prescription from UK biobank. Exposure was cardiometabolic risk burden, calculated as the sum of the presence of cardiometabolic risk factors, including obesity, diabetes, dyslipidemia and hypertension. GI bleeding obtained from hospital inpatient admissions was the outcome. The Cox proportional hazards model was used to calculate the hazard ratio (HR) and 95% confidence interval (CI).
resultsAfter a mean of 13.4 years of follow-up, we found that among 12,781 aspirin users, the incidence rate of GI bleeding was increasing with the growing cardiometabolic risk burden (number of cardiometabolic risk factors from 0 to 4), ranging from 4.53, 4.98, 5.47, 8.08 to 9.64 per 1000 person-years. As compared to participants without cardiometabolic risk factors and after adjustment for potential confounders, the elevated GI risk was greater with the increased burden with HR ranging from 1.09, 1.16, 1.59 to 1.95 (P-trend < 0.001), in which diabetes (HR = 1.24, 95% CI = 1.02-1.51) and hypertension (HR = 1.24, 95% CI = 1.08-1.42) may play a more pronounced role. Stratified analysis found that the association was stronger in those with history of gastrointestinal disorders, younger adults or males.
conclusionsAspirin users with higher burden of cardiometabolic risk experienced significantly higher risk of GI bleeding, calling for concern of tailored strategy for GI bleeding prevention in aspirin users related to cardiometabolic risk burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.